An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions

Trial Profile

An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPRINT
  • Sponsors 480 Biomedical
  • Most Recent Events

    • 03 Aug 2016 This trial has been discontinued in Austria, according to the European Clinical Trials Database.
    • 09 Feb 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018, according to ClinicalTrials.gov record.
    • 09 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top